Robotics
PrivateChina's humanoid volume champion and the cleanest pre-IPO embodied-AI bet on the board — but it is a subsidy-fed, almost-certainly-loss-making hardware ramp whose 17x "revenue" is half SOE order-book and half a full-stack story; own the listing event (HK 2026 / Swancor-STAR), not the unit economics, which nobody has yet seen.
Research
The verdict
China's humanoid volume champion and the cleanest pre-IPO embodied-AI bet on the board — but it is a subsidy-fed, almost-certainly-loss-making hardware ramp whose 17x "revenue" is half SOE order-book and half a full-stack story; own the listing event (HK 2026 / Swancor-STAR), not the unit economics, which nobody has yet seen.
What it is. AgiBot (brand for Shanghai Zhiyuan Robotics, founded February 2023) is a vertically-integrated humanoid-robot maker — hardware (bipedal + wheeled humanoids, dexterous hands), the embodied-AI "brain" (the GO-1/GO-2 foundation models), the data pipeline (the AgiBot World dataset + an "AIDEA" data factory), and a deployment/operations layer (LinkCraft, Lingqu OS). It positions itself not as a robot-body vendor but as a full-stack embodied-intelligence company. HQ Shanghai; first assembly plant stood up January 2024, a second in Pudong to push capacity past ~400 units/month.
How it makes money (today). Three revenue motions, all early:
Reported revenue. 2024 revenue ~60M yuan; 2025 revenue ~1.05B yuan — a ~17x jump, which the company claims makes it the fastest Chinese robotics firm to cross 1B yuan in revenue.
Customers / partners named (public): Longcheer (tablet production lines), Minth Group (full-portfolio launch in Germany, Mar 2026), Singtel Enterprise (first operator agreement, Singapore), plus unnamed SOEs (power/data-center/entertainment). International footprint claimed across Europe, North America, Japan, South Korea, Southeast Asia, the Middle East.
Why it matters. Alongside Unitree, AgiBot is one of the two anchors of China's humanoid volume market — and China shipped ~90% of the world's humanoid units in 2025. Western programs (Tesla, Figure, Boston Dynamics) own the capital and the attention; the Chinese duopoly owns the units.
Map: upstream components → AgiBot integration → end customer.
Chokepoints: (1) advanced compute (export-control single-point risk); (2) the SOE order channel (concentration — see Lens 13); (3) skilled teleoperation/data-labelling labor for the data factory (commoditizing, low risk). The Chinese actuator/sensor base is the opposite of a chokepoint — it is the moat (Lens 3).
Durable advantages — graded:
Bargaining power. Over suppliers: high (deep, fragmented Chinese component base — AgiBot is a large, scaling buyer). Over customers: low-to-negative on the SOE channel — when your anchor demand is state procurement, the state holds the pricing whip, and 10% buyer rebates mean the government is effectively setting the clearing price. Power over private/export customers is unproven.
Net: the moat that matters is the full-stack + data thesis; the cost moat is a Chinese-field commodity, not an AgiBot edge.
segments.csv is empty — AgiBot is private and discloses no segment P&L. Reconstructed qualitatively from public statements (n/a — private, not disclosed for all hard numbers):
| Segment | What | Disclosure | Trend |
|---|---|---|---|
| Industrial / SOE deployment | Power plants, data centers, manufacturing (Longcheer lines) | >2B yuan orders 2025 | Accelerating — the anchor |
| Logistics / retail / hospitality / education | Wheeled + humanoid platforms, "reception/explanation," store guides | Qualitative only | Accelerating (volume) |
| Software / models / data | GO-1/GO-2, AgiBot World dataset, LinkCraft, dev-kits | n/a — not disclosed | Strategic, not yet monetized at scale |
| International | Minth (DE), Singtel (SG), claimed multi-region | n/a — not disclosed | Early, thin |
Geographic: overwhelmingly China; export is a 2026 narrative, not yet a number. The honest read: there is no segment economics to analyze yet — only a top-line (1.05B yuan, contested) and an order book (2B yuan, unrecognized). That opacity is the finding.
Round history (all ``, unaudited; Chinese rounds frequently undisclosed on amount):
| Date | Round | Lead / notable | Valuation signal |
|---|---|---|---|
| 2023 (H1) | Angel/seed | Founding; Hillhouse, HongShan (ex-Sequoia China) early | — |
| 2023–24 | Multiple (≥8 rounds in ~2 yrs claimed) | BYD, SAIC Capital, BlueRun, CDH, Lanchi, etc. | Crossed unicorn ($1B+) by mid-2025 |
| 2025-03-24 | Series B | Led by Tencent; +Lanchi, Longcheer, Wolong, Zhuhai Huafa | Pre-money |
| 2025-08-01 | Series B (extension/tranche) | — | ~$2.09B |
| 2026-03 | (mark) | — | $2.1B per Pitchbook |
Total disclosed raised: ~$83.8M across 3 reported rounds (Tracxn) — but this is the disclosed slice; the 15B-yuan post-Series-B valuation implies far more capital absorbed than $83.8M, so the public raise figure is unreliable / incomplete for a Chinese company.
Burn signals. Not disclosed. Inference: a hardware company that 17x'd revenue, doubled plants, runs a data factory, and trains frontier VLA models is burning heavily — and Unitree, its closest comp with a profit, saw Q1-2026 adjusted net profit fall 52% purely on R&D + sales expansion even as revenue rose 68%. AgiBot, which has never disclosed a profit, is near-certainly loss-making at the net line. The 1.05B-yuan revenue is a scale flex, not a profit signal.
Valuation conflict (must surface): primary/secondary marks put AgiBot at ~$2.1B (Mar 2026); the HK IPO target is HK$40–50B (~$5.1–6.4B). That is a ~2.5–3x step-up the IPO would need to clear — the single biggest number-vs-number tension in this dossier. The IPO target essentially asks public markets to pay a Unitree-equivalent ($6.2B) multiple for a company that, unlike Unitree, has shown no profit.
No earnings calls. Proxy = founder/management public posture across 2024→2026:
Tone shift: spectacle (2024) → commercial-ROI (2025) → scale + full-stack-differentiation + revenue-leadership (2026). The phrases they added: "full-stack," "tangible customer value," "fastest to 1B yuan." The thing they conspicuously do not say: profitability, gross margin, or net loss. That silence is the tell.
Syndicate quality — strong, and an IPO-proximity tell. Reported cap table: founders ~48%, ESOP ~10%, Tencent ~7%, then a long tail (4.5%→1.5% each). Investor roster spans strategic corporates (Tencent, BYD, LG Electronics, JD.com, Baidu, SAIC Capital, Wolong, Longcheer), top-tier VC/PE (HongShan/ex-Sequoia China, Hillhouse, CDH, Warburg Pincus, BlueRun, Lanchi), and crossover/foreign capital (LG, Mirae Asset, Warburg Pincus). A Mirae/Warburg-grade crossover presence is exactly the late-stage signature that precedes a public listing.
Peer table (the cleanest comp is Unitree, which has a public STAR-Market prospectus):
| Metric | AgiBot | Unitree (filed) | Source |
|---|---|---|---|
| Status | Private; HK IPO 2026 + Swancor/STAR backdoor | STAR-Market IPO cleared Jun 1, 2026 | |
| Implied valuation | ~$2.1B (private mark); IPO target ~$5–6.4B | ||
| 2025 revenue | 1.699B yuan (~$250M), audited-prospectus | ||
| 2025 net profit | Not disclosed (likely loss) | ~590M yuan ex-nonrecurring | |
| Gross margin | n/a — not disclosed | ~60.1% (core) | |
| 2025 humanoid units | 5,168 (Omdia) / 10,000th unit Mar 2026 | ~5,500 (prospectus) / 4,200 (Omdia) | |
| Q1-26 trend | n/a | Rev +68% YoY; adj. net profit −52% (R&D/sales) | |
| EV/Sales (implied, IPO target) | ~$5–6.4B ÷ ~$145M ≈ 35–44x | ~$6.2B ÷ ~$250M ≈ 25x | |
| P/E | n/a — no profit | ~$6.2B ÷ ~$82M net ≈ ~75x | |
| EV/EBIT, div yield, 5y avg ROE | n/a / pre-profit | n/a — short history | — |
Shipment-data conflict (flag): Omdia (Jan 2026) ranks AgiBot #1 at 5,168 / Unitree 4,200 humanoid units for 2025; Unitree's own prospectus claims ~5,500. The "who shipped more" leadership claim is definitionally contested (humanoid-only vs all embodied units; ship vs produce). Do not treat AgiBot's #1 claim as settled.
Read: against the only audited peer, AgiBot is less revenue, no proven profit, no disclosed margin — yet seeking a richer multiple. Unitree is the benchmark the IPO will be priced against, and Unitree clears it on profitability where AgiBot, today, cannot.
Events that re-rated AgiBot's private valuation / narrative:
Pattern: AgiBot's marks move on (a) tier-1 capital entries, (b) production milestones, and (c) the listing machinery — not on disclosed financial performance (there is none to react to). The market is pricing scale + story + a near-term liquidity event, which is precisely the risk profile of a momentum pre-IPO name.
Track record: genuine — built a 10,000-unit-scale humanoid business and a competitive foundation model from a Feb-2023 standing start. Capital-allocation history (thin, two notable moves): (1) extending vertical integration into a data factory (defensible, on-strategy); (2) the Swancor acquisition — capital deployed into a wind-blade/composite-materials firm whose strategic fit is, charitably, indirect. If Swancor is a listing vehicle dressed as M&A, it is a governance/transparency yellow flag, even if legal.
Founder vs professional manager: a deliberate hybrid — founder-technologist (Peng) + professional-executive controller (Deng, ex-Huawei). For a capital-intensive hardware company chasing a public listing, the professional-CEO anchor is the right archetype; the open question is whether the Huawei-executive lineage is a competence asset or a state-/Huawei-adjacency liability in Western markets (export, procurement scrutiny).
Accounting / disclosure risks (private → mostly un-testable, which is itself the risk):
Regulatory findings. Per regulatory/regulatory-findings.md (fetched 2026-06-30): AgiBot has no CIK; no SEC EDGAR enforcement (LR/AAER) is possible — 0 SEC findings. Non-SEC web search ("AgiBot"/"Zhiyuan Robotics" + FTC/DOJ/FDA/CFPB/consent-decree/settlement/fine) returns no material enforcement actions, lawsuits, or penalties as of this date. No 10-K Item 3 exists (private/foreign). The live regulatory exposure is forward-looking, not historical: (1) Chinese CSRC/SSE review of the Swancor restructuring and any HK listing; (2) US export-control / entity-list risk given the Huawei-executive lineage, SOE customers, and dual-use humanoid tech — the most plausible future enforcement vector, currently unrealized. Net: no material regulatory or legal findings — verified via SEC EDGAR EFTS (none possible), web search, and the absence of any required public filing, as of 2026-06-30; all findings unaudited per public sources.
Readiness: 4–5 on the private-watch scale (pre-IPO / listing imminent). The milestones that unlock a listing are largely done or in motion:
Two parallel paths to "tradeable": (1) Swancor / Shanghai-STAR — already live, gives partial exposure now; (2) HK IPO — the clean, full-float event, H2-2026. The base-case window for a clean tradeable AgiBot is Q3–Q4 2026, with execution + China-market-window + audit-disclosure risk the three things that slip it.
Valuation framing (no EPS — pre-profit; `` only): at the IPO target ~$5–6.4B on ~$145M (contested) 2025 revenue, that is ~35–44x EV/Sales — vs Unitree's audited ~25x with a real 60% gross margin and ~590M-yuan profit. AgiBot must either (a) prove the revenue is higher/cleaner than skeptics think, or (b) grow into the multiple at >50% for several years, or (c) price below the rumored target. The honest base case: the listing happens in 2026; the price is the bet, and at the rumored level it is demanding.
No Brier forecast logged (--watchlist rule: skip forecast.ts create). If promoted to a thesis, the scoreable binary is "AgiBot completes a public listing (HK IPO or Swancor-STAR control transaction closes) by 2026-12-31," base-case p≈0.70.
Recommended overlay write-back (NOT executed under wave boundaries): add AgiBot to research/private-watch.json at readiness 4–5, catalyst "HK IPO H2-2026 / Swancor-STAR control deal," dossier: companies/agibot/deep-dive-2026-06-30.md. Flagged for Connor; not written.
Bull case. AgiBot is the purest, most-scaled pre-IPO embodied-AI bet investable, sitting on the right side of three structural forces: (1) China's $20B+-subsidized, 15th-Five-Year-Plan-blessed embodied-intelligence build-out, where it is a top-2 volume player; (2) a genuine full-stack + proprietary-data differentiation that GO-2's benchmark wins now substantiate, in a market where most "humanoids" still aren't running foundation models; (3) a credible, near-term liquidity event (HK 2026 + Swancor) backed by a Tencent/Mirae/Warburg-grade syndicate. If even the lower-bound humanoid TAM ($38B by 2035) lands and the Chinese duopoly holds ~80% domestic share, the volume champion with the best brain compounds. Contrarian view the market is refusing to see: the West is mispricing this as "another cheap Chinese hardware clone of Unitree" when the data-factory + GO-model stack may be the more durable asset than the body — and the SOE order book, however murky, is a demand floor Western peers don't have.
Bear case (permanent-impairment risks).
Pre-mortem (18 months out, thesis broke): AgiBot IPO'd in late 2026; the prospectus showed a large net loss and revealed ~half of 2025 "revenue" was SOE order recognition; the stock priced 40% below the HK$40–50B target; a domestic price war crushed unit margins; and an export-control designation shut the international channel. Volume kept rising, profit never came, the multiple compressed to Unitree's level on a worse margin profile.
Are multiples too high? At the rumored ~$5–6.4B / ~35–44x sales for a pre-profit company, yes — relative to the only audited peer. The bet is the re-rate the IPO would require, not the current private mark.
Dismantling the bull case:
A best-in-class MedTech compounder whose 8-9.5% organic engine is intact, but at ~20x forward EPS the stock already prices the cyber-attack recovery as a formality — the bet is that a $375M Q1 air-pocket is timing, not a dent in the franchise.
A genuine top-3 global robotaxi platform finally crossing city-level unit-economics breakeven — but priced for execution it has not yet earned, with a related-party-and-China-permit overhang that the −65% drawdown is screaming about; net-cash floor + founder 540-day lockup make it a WATCHING name to size on proof of fleet-scaling through the permit freeze, not a chase here.
A spine-implant roll-up wearing a robotics badge — the robot is <5% of revenue and a razor-and-blade pull-through, not the story; the real bet is whether mid-single-digit organic growth re-accelerates as NuVasive integration scars heal, at a justified ~16x value-medtech multiple.